Table 3.
Baseline characteristics of the subjects from studies included in the meta-analysis.
| Study |
Previous weight loss (%) |
Body weight (kg) |
Weight variation (kg) |
BMI (kg/m2) |
Lean mass (kg) |
IL 6 (pg/mL) |
CRP (mg/L) |
Albumin (g/L) |
|---|---|---|---|---|---|---|---|---|
| Oral supplementation | ||||||||
| Carvalho et al. (17) | (I) 13.0 ± 8.9 (C) 14.2 ± 5.0 |
(I) 55.8 (37.5–100.0)3 (C) 57.2 (40.3–80.1)3 |
NR | (I) 20.7 ± 3.4 (C) 22.6 ± 4.3 |
NR | (I) 2.58 (0–16.97)3 (C) 2.17 (0–14.34)3 |
(I) 0.41 (0.04–50.55)3 (C) 1.46 (0.06–20.11)3 |
(I) 4.40 (3.20–4.80)3 (C) 4.30 (2.70–5.20)3 |
| Faber et al. (18) | (I) −4.2 ± 6.0 (C) −3.8 ± 5.7 |
NR | NR | (I) 25.5 ± 4.6 (C) 25.4 ± 3.6 |
NR | (I) 0.0 (−0.5–1.2)4 (C) 0.0 (−1.5–0.1)3 |
(I) 0.5 (0.0–3.3)4 (C) 0.0 (−2.3–1.5)4 |
NR |
| Liu et al. (19) | (I) −0.10 to 0.07*22 (C) −0.12 to 0.10*22 |
NR | NR | NR | NR | (I) 113.11 to 126.2922 (C) 113.64 to 128.9622 |
NR | NR |
| Persson et al. (20) | (I) −13.2 ± 8.4 (C)-10.8 ± 8 |
(I) 56.6 (35–101)3 (C) 61.8 (33–80)3 |
(I) −0.6* (C) 1.8* |
(I) 21.6 ± 4.1 (C) 21.1 ± 4.8 |
NR | (I) 4.7 (1.5–7.6)3 (C) 4.9 (1.4–18.9)3 |
(I) 22.5 (10–124) (C) 633 (10–229) |
(I) 39 (27–48)3 (C) 34 (27–40)3 |
| Enteral nutritional supplementation | ||||||||
| Solís-Martínez et al. (21) | (I) 13.33 ± 8.10 (C) 13.74 ± 9.27 |
(I) 58.8 ± 14.0 (C) 61.1 ±11.5 |
(I) −0.3 ± 5.9 (C) −2.1 ± 3.7 |
(I) 22.6 ± 4.6 (C) 24 ± 4.2 |
(I) 39.4 ± 9.6 (C) 42.6 ± 9.5 |
(I) 333 ± 309.8 (C) 196.8 ± 256.4 |
(I) 21 ± 35 (C) 25 ± 38 |
(I) 3.79 ± 0.67 (C) 3.66 ± 0.49 |
| Yeh et al. (22) | NR | (I) 54.9 ± 9.4 (C) 54.5 ± 10.8 |
(I) 1.12 ± 8.03# (C) −6.30 ± 9.41# |
(I) 20.0 ± 3.1 (C) 19.8 ± 3.7 |
NR | NR | NR | (I) 3.2 ± 0.5 (C) 3.3 ± 0.5 |
1Values are mean ± SD unless otherwise specified.
I, intervention group; C, Counterpart group; BMI, body mass index; NR, not reported.
2
Estimated point 95%CI.
3
Median (range).
4
Median (IQR).
*
Values are kilograms (kg).
#
Values are percentage (%).